F.D.A. Approves a Drug for Late-Stage Pancreatic Cancer

The Food and Drug Administration has approved Abraxane, which in a clinical trial prolonged the lives of patients by a little less than two months on average.    

Source: NYT Health - September 6, 2013 Category: Consumer Health News Authors: By ANDREW POLLACK Tags: Pancreatic Cancer Clinical Trials JPMorgan Chase & Company JPM NYSE Drugs (Pharmaceuticals) Food and Drug Administration Celgene Corporation CELG NASDAQ Abraxis BioScience, Incorporated ABBI NASDAQ Abraxane (Drug) (Des) Source Type: news